Our Blog

Channelling Rage: The Surprising Power of a Rage Friend

Dr Tom MacLaren, Consultant Psychiatrist at Re:Cognition Health was featured in an article in the Daily Mail about having a “rage friend”, someone you can trust to […]

The Importance of Men Talking About Mental Health

In recent years, conversations around mental health have become more common and accepted, yet many men still struggle to open up about their own experiences. Despite progress […]

10 Signs You Might Have ADHD (and tips to address them)

ADHD (Attention Deficit Hyperactivity Disorder) can manifest in various ways, and it affects both children and adults. While everyone experiences some of these symptoms from time to […]

Lifestyle Changes to help Reduce the Risk of Dementia

Understanding the risk factors for dementia, including lifestyle choices and health conditions, is crucial in preventing cognitive decline. Dr Emer MacSweeney, CEO, Medical Director and Consultant Neuroradiologist […]

Understanding ARIA – a recognised side-effect of new Alzheimer’s medications

ARIA, or Amyloid-Related Imaging Abnormalities, is a recognised side-effect of lecanemab (Lequembi™) and donanemab and other medications in the same class. These medications are monoclonal antibodies (MABs) […]

Understanding Lecanemab (Leqembi™): A Breakthrough in Alzheimer’s Treatment

Lecanemab, also known by its name Leqembi™, represents a significant milestone in the ongoing battle against Alzheimer’s disease. This innovative drug offers new hope to patients living […]

Giving Hope Through Clinical Trials – David’s Story

David was diagnosed with Alzheimer’s in 2016 after experiencing problems with his memory. Below he shares his story about joining the Clarity clinical trial at Re:Cognition Health, […]

A New Milestone in Alzheimer’s Treatment: MHRA Approves Lecanemab (Leqembi™)

PRESS RELEASE. Re:Cognition Health is delighted to offer this new treatment Re:Cognition Health is delighted with the announcement that the MHRA has approved Lecanemab, a pioneering treatment […]

Vision Loss and Cholesterol Linked to Dementia

The latest report from the Lancet Commission presents groundbreaking findings suggesting that treating failing eyesight and high cholesterol could be pivotal in lowering the risk of developing […]

The Potential of Ozempic in Treating Alzheimer’s and Depression: A Promising Horizon

Medications such as Ozempic and Wegovy, both of which contain Semaglutide, a GLP-1 receptor, were originally designed to treat type 2 diabetes and obesity, however, their potential […]